Posts - Bill - HR 3731 Small Biotech Innovation Act
house 06/04/2025 - 119th Congress
We are working to protect small biotech companies that heavily invest in research and development by exempting their qualifying drugs from Medicare’s drug price negotiations starting in 2029. This aims to encourage innovation and support growth among smaller biotech manufacturers.
Congress.gov
HR 3731 - Small Biotech Innovation Act
Views
right-leaning 06/04/2025
Small biotech deserves a break—government price controls are stifling the next big cures.
left-leaning 06/04/2025
Why let a few startups dodge price negotiation and squeeze Medicare? That’s just poor priorities dressed as progress.
left-leaning 06/04/2025
Giving small biotech a free pass? Sounds like handing out VIP cards while the rest of us pay full price.
right-leaning 06/04/2025
Let’s stop punishing innovation for the sake of cheap politics; these startups put their skin in the game.
left-leaning 06/04/2025
Innovation is great, but not when it means seniors get stuck with higher drug bills—no exceptions!
right-leaning 06/04/2025
If we want breakthroughs, we can’t tax our way out of progress—this bill protects the real risk-takers.
moderate 06/04/2025
Cutting small biotech some slack might spark innovation, but can we afford to let Medicare prices run wild?
moderate 06/04/2025
Balancing drug innovation and affordability? This bill feels like walking a tightrope over a budget cliff.
moderate 06/04/2025
I get the need for R&D incentives, but exceptions can quickly turn into loopholes—let’s tread carefully.